Mammalian cell cultures
George LovreczBioManufacturing, CSIRO
343 Royal Parade
Parkville, Vic. 3052, Australia
Tel: +61 3 9662 7348, or +61 3 9545 7862 (Clayton)
Email: george.lovrecz@csiro.au
Microbiology Australia 38(2) 67-69 https://doi.org/10.1071/MA17030
Published: 22 March 2017
Abstract
There is increasing demand worldwide for high-quality complex proteins for treating diseases and for clinical and pre-clinical studies involving recombinant proteins, vaccines, and monoclonal antibodies, many of which are the products of mammalian cell cultures. Biologics or protein-based drugs had a global market over US$200 billion in 2016, with eight of the top 10 selling drugs with a combined global sales over US$55 billion produced using mammalian cell cultures1,2. Recombinant proteins are also significant global economic drivers of both vaccine and biomarker development. In addition, it is estimated that more than half of the Australian biotechnology companies are utilising mammalian cell culture or their products3.
References
[1] EvaluatePharma® World Preview (2016) Outlook to 2022. 9th edition.[2] https://www.drugs.com/slideshow/looking-ahead-pharma-projections-for-2016-and-beyond-1230
[3] Australasian Biotechnology (2016) AusBioSTOCK. The Journal of AusBiotech 26, 86–90.
[4] Freshney, R.I. (2016) Culture of Animal Cells. 7th edition. Wiley Blackwell.
[5] Nielsen, J. et al. (2013) Production of biopharmaceutical proteins by yeast. Advances through metabolic engineering. Bioengineered 4, 207–211.
| Production of biopharmaceutical proteins by yeast. Advances through metabolic engineering.Crossref | GoogleScholarGoogle Scholar |
[6] Kotzsch, A. et al. (2011) A secretory system for bacterial production of high-profile protein targets. Protein Sci. 20, 597–609.
| A secretory system for bacterial production of high-profile protein targets.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3MXjvFWnu7c%3D&md5=075fa272030d65596145b2d6822239bfCAS |
[7] Wurm, F.M. (2004) Review: production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotechnol. 22, 1393–1398.
| Review: production of recombinant protein therapeutics in cultivated mammalian cells.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD2cXptlSls7k%3D&md5=b58e21014be5dbd067cb7a97f02ecaa7CAS |
[8] Mammalian Cell Cultures for Biologics Manufacturing (2014) Advances in Biochemical Engineering/Biotechnology 139 (Zhou, W. and Kantardjieff, A. eds)
[9] Khan, K.H. (2013) Gene expression in mammalian cells and its applications. Adv. Pharm. Bull. 3, 257–263.
[10] Walsh, G. (2014) Biopharmaceutical benchmarks. Nat. Biotechnol. 32, 992–1000.
| Biopharmaceutical benchmarks.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2cXhslaqs7nP&md5=600467f2ed561354e6e50a2c33c0be5eCAS |
[11] Ryan, J. (2004) General Guide for Cryogenically Storing Animal Cell Cultures. Corning Life Sciences Technical Bulletin: https://www.corning.com/media/worldwide/cls/documents/t_cryoanimalcc.pdf
[12] Shukla, A.A. and Gottschalk, U. (2013) Single-use disposable technologies for biopharmaceutical manufacturing. Trends Biotechnol. 31, 147–154.
| Single-use disposable technologies for biopharmaceutical manufacturing.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38XhslWqtb7N&md5=f70d999cfbd2d5c6377998a316214cbbCAS |
[13] Kelley, B. (2009) Industrialization of mAB production technology: the bioprocessing industry at a crossroads. MAbs 1, 443–452.
| Industrialization of mAB production technology: the bioprocessing industry at a crossroads.Crossref | GoogleScholarGoogle Scholar |
[14] http://gabi-journal.net/
